,pubmed_id,title,abstract,keywords,journal,publication_date,authors,methods,conclusions,results,copyrights,doi,xml,efficacy,size,StudyType,SymptomsTreated,Trend,SymptomsTreated_1
0,36695682,Nonskeletal and skeletal effects of high doses versus low doses of vitamin D,"Vitamin D sufficiency is associated with a reduced risk of fractures, diabetes mellitus, cardiovascular events, and cancers, which are frequent complications after renal transplantation. The VITALE (VITamin D supplementation in renAL transplant recipients) study is a multicenter double-blind randomized trial, including nondiabetic adult renal transplant recipients with serum 25-hydroxy vitamin D (25(OH) vitamin D) levels of <30 ng/mL, which is randomized 12 to 48 months after transplantation to receive high (100 000 IU) or low doses (12 000 IU) of cholecalciferol every 2 weeks for 2 months and then monthly for 22 months. The primary outcome was a composite endpoint, including diabetes mellitus, major cardiovascular events, cancer, and death. Of 536 inclusions (50.8 [13.7] years, 335 men), 269 and 267 inclusions were in the high-dose and low-dose groups, respectively. The serum 25(OH) vitamin D levels increased by 23 versus 6 ng/mL in the high-dose and low-dose groups, respectively (P < .0001). In the intent-to-treat analysis, 15% versus 16% of the patients in the high-dose and low-dose groups, respectively, experienced a first event of the composite endpoint (hazard ratio, 0.94 [0.60-1.48]; P = .78), whereas 1% and 4% of patients in the high-dose and low-dose groups, respectively, experienced an incident symptomatic fracture (odds ratio, 0.24 [0.07-0.86], P = .03). The incidence of adverse events was similar between the groups. After renal transplantation, high doses of cholecalciferol are safe but do not reduce extraskeletal complications (trial registration: ClinicalTrials.gov; identifier: NCT01431430).","['clinical research/practice', 'clinical trial', 'complication: malignant', 'complication: medical/metabolic', 'hyperparathyroidism', 'kidney disease: metabolic', 'kidney transplantation/nephrology']",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,2023-01-26,"[{'lastname': 'Courbebaisse', 'firstname': 'Marie', 'initials': 'M', 'affiliation': 'Paris University; Physiology Department, European Georges-Pompidou Hospital, APHP; INSERM U1151. Paris, France. Electronic address: marie.courbebaisse@aphp.fr.'}, {'lastname': 'Bourmaud', 'firstname': 'Aurelie', 'initials': 'A', 'affiliation': ""APHP.Nord-Université de Paris, Hôpital Universitaire Robert Debré, Unité d'Epidémiologie Clinique, Inserm, CIC 1426, F-75019 Paris, France; Université de Paris, ECEVE UMR 1123, INSERM. F-75010 Paris, France.""}, {'lastname': 'Souberbielle', 'firstname': 'Jean-Claude', 'initials': 'JC', 'affiliation': 'Service des explorations fonctionnelles hôpital Necker-Enfants Malades, DMU Biophygen, GHU Centre Université de Paris APHP. Paris, France.'}, {'lastname': 'Sberro-Soussan', 'firstname': 'Rebecca', 'initials': 'R', 'affiliation': 'Université de Paris; Service de Transplantation Rénale et Néphrologie, Hôpital Necker Enfant Malades, APHP. Paris, France.'}, {'lastname': 'Moal', 'firstname': 'Valérie', 'initials': 'V', 'affiliation': 'Aix-Marseille Université - AP-HM - Hôpital Conception - Centre de Néphrologie et Transplantation Rénale. Marseille, France.'}, {'lastname': 'Le Meur', 'firstname': 'Yannick', 'initials': 'Y', 'affiliation': 'Department of Nephrology, CHU de Brest; UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, Labex IGO. Brest, France.'}, {'lastname': 'Kamar', 'firstname': 'Nassim', 'initials': 'N', 'affiliation': 'Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, INSERM U1043, IFR -BMT, University Paul Sabatier. Toulouse, France.'}, {'lastname': 'Albano', 'firstname': 'Laetitia', 'initials': 'L', 'affiliation': 'Service de Transplantation Rénale, CHU de Nice. Nice, France.'}, {'lastname': 'Thierry', 'firstname': 'Antoine', 'initials': 'A', 'affiliation': 'Service de Néphrologie, INSERM U1082 et Fédération Hospitalo-Universitaire BIOSUPORT. Poitiers, France.'}, {'lastname': 'Dantal', 'firstname': 'Jacques', 'initials': 'J', 'affiliation': 'CRTI (Centre de Recherche en Transplantation et Immunologie) INSERM UMR1064, Université de Nantes, Centre Hospitalier Universitaire de Nantes. Nantes, France.'}, {'lastname': 'Danthu', 'firstname': 'Clément', 'initials': 'C', 'affiliation': 'Department of Nephrology, Limoges University hospital; UMR INSERM 1092, RESINFIT, Limoges University hospital 2. Limoges, France.'}, {'lastname': 'Moreau', 'firstname': 'Karine', 'initials': 'K', 'affiliation': 'Unité de transplantation rénale, Hôpital Pellegrin, CHU de Bordeaux. Bordeaux, France.'}, {'lastname': 'Morelon', 'firstname': 'Emmanuel', 'initials': 'E', 'affiliation': 'Service de transplantation, néphrologie et immunologie clinique, Hôpital Edouard Herriot, Hospices Civils de Lyon; INSERM U1111, Université Claude Bernard Lyon1. Lyon, France.'}, {'lastname': 'Heng', 'firstname': 'Anne-Elisabeth', 'initials': 'AE', 'affiliation': 'Service de Néphrologie, Dialyse, Transplantation, CHU de Clermont-Ferrand; Université Clermont Auvergne. F-63000 Clermont-Ferrand, France.'}, {'lastname': 'Bertrand', 'firstname': 'Dominique', 'initials': 'D', 'affiliation': 'Nephrology, dialysis and kidney transplantation, Rouen University Hospital. Rouen, France.'}, {'lastname': 'Arzouk', 'firstname': 'Nadia', 'initials': 'N', 'affiliation': 'Service de Transplantation Rénale, hôpital La Pitié-Salpétrière, APHP. Paris, France.'}, {'lastname': 'Perrin', 'firstname': 'Peggy', 'initials': 'P', 'affiliation': 'Department of Nephrology and Transplantation, Strasbourg University Hospital; Fédération de Médecine Translationnelle, INSERM U1109, LabEx TRANSPLANTEX. Strasbourg, France.'}, {'lastname': 'Morin', 'firstname': 'Marie-Pascale', 'initials': 'MP', 'affiliation': 'CHU Pontchaillou, service de Néphrologie. Rennes, France.'}, {'lastname': 'Rieu', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'Division of Nephrology, Reims university hospital, CRNS UMR 7369 MEDyC laboratory. Reims, France.'}, {'lastname': 'Presne', 'firstname': 'Claire', 'initials': 'C', 'affiliation': 'Nephrology Internal Medicine Dialysis Transplantation Department, Amiens University Hospital. Amiens France.'}, {'lastname': 'Grimbert', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'Nephrology and Transplant Department, CHU Henri-Mondor, APHP; Université Paris Est Créteil, INSERM U955. Paris, France.'}, {'lastname': 'Ducloux', 'firstname': 'Didier', 'initials': 'D', 'affiliation': 'Department of Nephrology, CHU Besançon. Besançon, France.'}, {'lastname': 'Büchler', 'firstname': 'Matthias', 'initials': 'M', 'affiliation': 'Department of Nephrology and Transplantation, CHU Tours; University of Tours, EA4245 Transplantation, Immunology, Inflammation; FHU SUPORT. Tours, France.'}, {'lastname': 'Le Quintrec', 'firstname': 'Moglie', 'initials': 'M', 'affiliation': 'Hôpital Foch, Nephrology department. Suresnes, France.'}, {'lastname': 'Ouali', 'firstname': 'Nacéra', 'initials': 'N', 'affiliation': 'Nephrology department, SINRA, Hôpital Tenon. Paris, France.'}, {'lastname': 'Pernin', 'firstname': 'Vincent', 'initials': 'V', 'affiliation': 'University of Montpellier, Department of Nephrology, Dialysis and Transplantation, Montpellier University hospital; Institute for Regenerative Medicine & Biotherapy (IRMB), INSERM U1183. Montpellier, France.'}, {'lastname': 'Bouvier', 'firstname': 'Nicolas', 'initials': 'N', 'affiliation': 'Service de Néphrologie-Dialyse-Transplantation, CHU Caen Normandie; Université de Caen Normandie. Caen, France.'}, {'lastname': 'Durrbach', 'firstname': 'Antoine', 'initials': 'A', 'affiliation': 'Université Paris Saclay, France; INSERM UMR 1186, Gustave Roussy. Villejuif, France; Nephrology Department, Bicêtre Hospital APHP. Le Kremlin-Bicêtre, France.'}, {'lastname': 'Alamartine', 'firstname': 'Eric', 'initials': 'E', 'affiliation': 'CHU de Saint Etienne et CIRI - INSERM U1111 - CNRS UMR5308 - ENS Lyon/UCBL1/Université St Etienne. Saint Etienne, France.'}, {'lastname': 'Randoux', 'firstname': 'Christine', 'initials': 'C', 'affiliation': 'Service de Néphrologie, CHU Bichat Claude Bernard, APHP.Nord. Paris, France.'}, {'lastname': 'Besson', 'firstname': 'Virginie', 'initials': 'V', 'affiliation': ""Service de Néphrologie-Dialyse-transplantation, CHU d'Angers. Angers, France.""}, {'lastname': 'Hazzan', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Université de Lille, INSERM, CHU Lille, U1286 - Infinite - Institute for Translational Research in Inflammation. F-59000 Lille, France.'}, {'lastname': 'Pages', 'firstname': 'Justine', 'initials': 'J', 'affiliation': ""APHP.Nord-Université de Paris, Hôpital Universitaire Robert Debré, Unité d'Epidémiologie Clinique, INSERM, CIC 1426. F-75019 Paris, France.""}, {'lastname': 'Colas', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': 'Unité de Recherche Clinique Necker-Cochin, APHP. Paris, France.'}, {'lastname': 'Piketty', 'firstname': 'Marie-Liesse', 'initials': 'ML', 'affiliation': 'Service des explorations fonctionnelles hôpital Necker-Enfants Malades, DMU Biophygen, GHU Centre Université de Paris APHP. Paris, France.'}, {'lastname': 'Friedlander', 'firstname': 'Gérard', 'initials': 'G', 'affiliation': 'Fondation Université de Paris. Paris, France.'}, {'lastname': 'Prié', 'firstname': 'Dominique', 'initials': 'D', 'affiliation': 'Université de Paris; INSERM U1151, service des explorations fonctionnelles hôpital Necker-Enfants Malades, DMU Biophygen, GHU Centre Université de Paris APHP. Paris, France.'}, {'lastname': 'Alberti', 'firstname': 'Corinne', 'initials': 'C', 'affiliation': ""APHP.Nord-Université de Paris, Hôpital Universitaire Robert Debré, Unité d'Epidémiologie Clinique, Inserm, CIC 1426, F-75019 Paris, France; Université de Paris, ECEVE UMR 1123, INSERM. F-75010 Paris, France.""}, {'lastname': 'Thervet', 'firstname': 'Eric', 'initials': 'E', 'affiliation': 'Paris University; Nephrology Department, European Georges-Pompidou Hospital, APHP; INSERM UMR 970, Paris Cardiovascular Research Center. Paris, France.'}]",,,,Copyright © 2022 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.,10.1016/j.ajt.2022.12.007,<Element 'PubmedArticle' at 0x12ec0ea70>,No Effect,None,None,['None'],None,None
1,"36648947
24036014
28251933
30415629
30796437
31215980
33206192
35082139
32491181
33534730
25372709
23393431
30615949
33513226
23509103
22262154
30790351
31173679
21986389
26767629
24256378
29080641
34100077
30635021
31669447
10966885
17131943
21613554
34327018
33210060
19833894
28007531
22114830",Association of Body Weight With Response to Vitamin D Supplementation and Metabolism.,"In the Vitamin D and Omega-3 Trial (VITAL), the effects of randomized vitamin D supplementation (cholecalciferol), 2000 IU/d, reduced the risk of several health outcomes among participants with normal, but not elevated, body weights. It was unclear whether weight had any association with the outcomes of the supplementation.
To investigate whether baseline body mass index (BMI) modifies vitamin D metabolism and response to supplementation.
VITAL is a completed randomized, double-blind, placebo-controlled trial for the primary prevention of cancer and cardiovascular disease. In the present cohort study, an analysis was conducted in a subset of VITAL participants who provided a blood sample at baseline and a subset with a repeated sample at 2 years' follow-up. VITAL was conducted from July 1, 2010, to November 10, 2018; data analysis for the present study was conducted from August 1, 2021, to November 9, 2021.
Treatment outcomes of vitamin D, 2000 IU/d, supplementation vs placebo associated with clinical and novel vitamin D-related biomarkers by BMI category adjusted for other factors associated with vitamin D status.
Multivariable-adjusted means (SE) or 95% CIs of vitamin D-related serum biomarkers at baseline and follow-up: total 25-hydroxyvitamin D (25-OHD), 25-OHD3, free vitamin D (FVD), bioavailable vitamin D (BioD), vitamin D-binding protein (VDBP), albumin, parathyroid hormone (PTH), and calcium, and log-transformed as needed.
A total of 16 515 participants (mean [SD] age, 67.7 [7.0] years; 8371 women [50.7%]; 12420 non-Hispanic White [76.9%]) were analyzed at baseline, including 2742 with a follow-up blood sample. Before randomization, serum total 25-OHD levels were incrementally lower at higher BMI categories (adjusted mean [SE]: underweight, 32.3 [0.7] ng/mL; normal weight, 32.3 [0.1] ng/mL; overweight, 30.5 [0.1] ng/mL; obesity class I, 29.0 [0.2] ng/mL; and obesity class II, 28.0 [0.2] ng/mL; P < .001 for linear trend). Similarly, baseline 25-OHD3, FVD, BioD, VDBP, albumin, and calcium levels were lower with higher BMI, while PTH level was higher (all P < .001 for linear trend). Compared with placebo, randomization to vitamin D supplementation was associated with an increase in total 25-OHD, 25-OHD3, FVD, and BioD levels compared with placebo at 2 years' follow-up, but increases were significantly lower at higher BMI categories (all treatment effect interactions P < .001). Supplementation did not substantially change VDBP, albumin, PTH, or calcium levels.
In this randomized cohort study, vitamin D supplementation increased serum vitamin D-related biomarkers, with a blunted response observed for participants with overweight or obesity at baseline. These longitudinal findings suggest that BMI may be associated with modified response to vitamin D supplementation and may in part explain the observed diminished outcomes of supplementation for various health outcomes among individuals with higher BMI.",[],JAMA network open,2023-01-18,"[{'lastname': 'Tobias', 'firstname': 'Deirdre K', 'initials': 'DK', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.\nDepartment of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Luttmann-Gibson', 'firstname': 'Heike', 'initials': 'H', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.\nDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Mora', 'firstname': 'Samia', 'initials': 'S', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.\nDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'lastname': 'Danik', 'firstname': 'Jacqueline', 'initials': 'J', 'affiliation': 'Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston.'}, {'lastname': 'Bubes', 'firstname': 'Vadim', 'initials': 'V', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'lastname': 'Copeland', 'firstname': 'Trisha', 'initials': 'T', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'lastname': 'LeBoff', 'firstname': 'Meryl S', 'initials': 'MS', 'affiliation': ""Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'lastname': 'Cook', 'firstname': 'Nancy R', 'initials': 'NR', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Lee', 'firstname': 'I-Min', 'initials': 'IM', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Buring', 'firstname': 'Julie E', 'initials': 'JE', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Manson', 'firstname': 'JoAnn E', 'initials': 'JE', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.""}]",,,"A total of 16 515 participants (mean [SD] age, 67.7 [7.0] years; 8371 women [50.7%]; 12420 non-Hispanic White [76.9%]) were analyzed at baseline, including 2742 with a follow-up blood sample. Before randomization, serum total 25-OHD levels were incrementally lower at higher BMI categories (adjusted mean [SE]: underweight, 32.3 [0.7] ng/mL; normal weight, 32.3 [0.1] ng/mL; overweight, 30.5 [0.1] ng/mL; obesity class I, 29.0 [0.2] ng/mL; and obesity class II, 28.0 [0.2] ng/mL; P < .001 for linear trend). Similarly, baseline 25-OHD3, FVD, BioD, VDBP, albumin, and calcium levels were lower with higher BMI, while PTH level was higher (all P < .001 for linear trend). Compared with placebo, randomization to vitamin D supplementation was associated with an increase in total 25-OHD, 25-OHD3, FVD, and BioD levels compared with placebo at 2 years' follow-up, but increases were significantly lower at higher BMI categories (all treatment effect interactions P < .001). Supplementation did not substantially change VDBP, albumin, PTH, or calcium levels.",,"10.1001/jamanetworkopen.2022.50681
10.1016/j.ypmed.2013.08.026
10.3945/ajcn.116.140392
10.1056/NEJMoa1809944
10.1093/annonc/mdz059
10.1001/jamacardio.2019.1870
10.1001/jamanetworkopen.2020.25850
10.1136/bmj-2021-066452
10.1210/clinem/dgaa335
10.2337/dc19-1708
10.1371/journal.pone.0111265
10.1371/journal.pmed.1001383
10.1016/j.metabol.2018.12.010
10.1210/clinem/dgaa981
10.1210/jc.2012-3369
10.1038/oby.2011.404
10.1002/jbmr.3686
10.1056/NEJMoa1900906
10.1016/j.cct.2011.09.009
10.1016/j.cct.2015.12.022
10.1056/NEJMoa1306357
10.1016/j.ecl.2017.07.012
10.1093/ije/dyab050
10.1186/s13063-018-3108-3
10.1016/j.cct.2019.105854
10.1093/ajcn/72.3.690
10.1111/j.1753-4887.2006.tb00180.x
10.3945/ajcn.111.015552
10.1155/2021/6647328
10.1002/jbm4.10397
10.2337/db09-1011
10.1016/j.jsbmb.2016.12.008
10.1016/j.amjmed.2011.07.009",<Element 'PubmedArticle' at 0x12ec226b0>,No Effect,16515,Analysis,"['25-OHD, 25-OHD3, FVD, BioD, VDBP, Albumin, PTH, and Calcium']",Decreasing Vitamin D Levels with Increasing BMI,"25-OHD, 25-OHD3, FVD, BioD, VDBP, Albumin, PTH, and Calcium"
2,36604262,Vitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial.,"Vitamin D has mostly been tested in Western populations. We examined the effect of high dose vitamin D in a population drawn predominantly from outside of Western countries.
This randomized trial tested vitamin D 60,000 IU monthly in 5670 participants without vascular disease but at increased CV risk. The primary outcome was fracture. The secondary outcome was the composite of CV death, myocardial infarction stroke, cancer, fracture or fall. Death was a pre-specified outcome. Mean age was 63.9 years, and 3005 (53.0%) were female. 3034 (53.5%) participants resided in South Asia, 1904 (33.6%) in South East Asia, 480 (8.5%) in South America, and 252 (4.4%) in other regions. Mean follow-up was 4.6 years. A fracture occurred in 20 participants (0.2 per 100 person years) assigned to vitamin D, and 19 (0.1 per 100 person years) assigned to placebo (HR 1.06, 95% CI 0.57-1.99, p-value = 0.86). The secondary outcome occurred in 222 participants (1.8 per 100 person years) assigned to vitamin D, and 198 (1.6 per 100 person years) assigned to placebo (HR 1.13, 95% CI 0.93-1.37, p = 0.22). 172 (1.3 per 100 person years) participants assigned to vitamin D died, compared with 135 (1.0 per 100 person years) assigned to placebo (HR 1.29, 95% CI 1.03-1.61, p = 0.03).
In a population predominantly from South Asia, South East Asia and South America, high-dose vitamin D did not reduce adverse skeletal or non-skeletal outcomes. Higher mortality was observed in the vitamin D group.
NCT01646437.","['Cancer', 'Cardiovascular disease', 'Death', 'Falls', 'Fractures', 'Vitamin D']","Nutrition, metabolism, and cardiovascular diseases : NMCD",2023-01-06,"[{'lastname': 'Joseph', 'firstname': 'P', 'initials': 'P', 'affiliation': 'Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. Electronic address: philip.joseph@phri.ca.'}, {'lastname': 'Pais', 'firstname': 'P', 'initials': 'P', 'affiliation': ""St. John's Medical College, Bangalore, India.""}, {'lastname': 'Gao', 'firstname': 'P', 'initials': 'P', 'affiliation': 'Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'lastname': 'Teo', 'firstname': 'K', 'initials': 'K', 'affiliation': 'Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'lastname': 'Xavier', 'firstname': 'D', 'initials': 'D', 'affiliation': ""St. John's Medical College, Bangalore, India.""}, {'lastname': 'Lopez-Jaramillo', 'firstname': 'P', 'initials': 'P', 'affiliation': 'Masira Research Institute Medical School, Universidad de Santander, Bucaramanga, Colombia.'}, {'lastname': 'Yusoff', 'firstname': 'K', 'initials': 'K', 'affiliation': 'UiTM Selayang, Selangor and UCSI University, Cheras, Kuala Lumpur, Malaysia.'}, {'lastname': 'Santoso', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Universitas Indonesia, National Cardiovascular Centre, Jakarta, Indonesia.'}, {'lastname': 'Gamra', 'firstname': 'H', 'initials': 'H', 'affiliation': 'Fattouma Bourguiba University Hospital and University of Monastir, Tunisia.'}, {'lastname': 'Talukder', 'firstname': 'S H', 'initials': 'SH', 'affiliation': 'Eminence, Dhaka, Bangladesh.'}, {'lastname': 'Christou', 'firstname': 'C', 'initials': 'C', 'affiliation': 'Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'lastname': 'Dagenais', 'firstname': 'G', 'initials': 'G', 'affiliation': 'Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Canada.'}, {'lastname': 'Tyrwhitt', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'lastname': 'Bosch', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'lastname': 'Dans', 'firstname': 'A', 'initials': 'A', 'affiliation': 'University of the Philippines, Manila, Philippines.'}, {'lastname': 'Yusuf', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,"In a population predominantly from South Asia, South East Asia and South America, high-dose vitamin D did not reduce adverse skeletal or non-skeletal outcomes. Higher mortality was observed in the vitamin D group.",,"Copyright © 2022 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.",10.1016/j.numecd.2022.11.001,<Element 'PubmedArticle' at 0x12ec37a60>,No Effect,1030,Randomized Control Trials,['Mortality'],Higher Mortality was observed in the Vitamin D group,Mortality
3,"36593062
28817104
22207629
24582912
21964001
17296473
20427238
16595781
22552031
20208539
26653112
26479950
32674255
21746882
19843932
25279717
15501394
20227496
21179201
16341266
22084438
15746048
20473951
19064967
19856313
19577568
15322536
20682706
16428488
22471961
23999998
8541028
24076584
26401986
16322555
31756952
16973386
28926770
33910812
32753685
31892604
34230167",Vitamin D,"Vitamin D
Twenty-eight patients were randomized to one of two groups: Untreated or treatment with VD
Serum VD
Our findings suggest that VD","['Colorectal cancer', 'PBMC', 'TGF-β1', 'cholecalciferol', 'interleukin-10', 'regulatory T-cells']","In vivo (Athens, Greece)",2023-01-03,"[{'lastname': 'Srichomchey', 'firstname': 'Patnapa', 'initials': 'P', 'affiliation': 'Graduate Program in Integrative Medicine, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand.\nCenter of Nutrition and Dietetics, Theptarin Hospital, Bangkok, Thailand.'}, {'lastname': 'Sukprasert', 'firstname': 'Sophida', 'initials': 'S', 'affiliation': 'Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand; sophida@tu.ac.th.'}, {'lastname': 'Khulasittijinda', 'firstname': 'Nathapong', 'initials': 'N', 'affiliation': 'Department of Surgery, Police General Hospital, Bangkok, Thailand.'}, {'lastname': 'Voravud', 'firstname': 'Narin', 'initials': 'N', 'affiliation': 'Section of Medical Oncology Unit, Department of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand.'}, {'lastname': 'Sahakitrungruang', 'firstname': 'Chucheep', 'initials': 'C', 'affiliation': 'Colorectal Surgery Division, Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'lastname': 'Lumjiaktase', 'firstname': 'Putthapoom', 'initials': 'P', 'affiliation': 'Clinical Immunology Laboratory, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Salaya, Thailand putthapoom@gmail.com.'}]",,Our findings suggest that VD,Serum VD,"Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.","10.21873/invivo.13078
10.3390/cancers9080108
10.1136/gutjnl-2011-300970
10.1016/j.ejca.2014.02.006
10.1634/theoncologist.2011-0151
10.1016/j.jpainsymman.2011.12.110
10.1016/j.amepre.2006.11.004
10.1016/j.coph.2010.04.001
10.1093/jnci/djj101
10.3945/ajcn.111.031070
10.1038/ni.1851
10.1210/jc.2015-3599
10.3109/10408363.2015.1094443
10.3390/cancers12071888
10.1128/MCB.05020-11
10.4049/jimmunol.0803217
10.1371/journal.pone.0109194
10.1016/j.jaut.2004.06.004
10.1016/j.jsbmb.2010.02.029
10.1371/journal.pone.0015235
10.1172/JCI21759
10.4049/jimmunol.1101638
10.1158/1078-0432.CCR-04-1869
10.1002/ijc.25464
10.1200/JCO.2008.18.7229
10.1002/ijc.24989
10.1053/j.gastro.2009.06.053
10.32598/IMMUNOREGULATION.1.1.5
10.1038/nm1093
10.1158/1078-0432.CCR-10-1073
10.1158/1078-0432.CCR-05-1886
10.1186/1471-2407-12-134
10.1007/s00394-013-0579-6
10.3109/07853899509002465
10.1097/CCO.0000000000000006
10.1159/000439278
10.1101/gad.1350705
10.3390/ijms20235822
10.1016/j.immuni.2006.07.011
10.48550/arXiv.1304.7193
10.1016/j.molimm.2017.09.006
10.21873/invivo.12387
10.1038/s41598-020-70078-y
10.21873/anticanres.13977
10.21873/anticanres.15159",<Element 'PubmedArticle' at 0x12ec48bd0>,Directionally Significant,1000,Randomized Control Trials,"['Pain, Mobility, and Quality of Life']",Positive Correlation between Vitamin D levels and Mobility,"Pain, Mobility, and Quality of Life"
4,"36591342
16315387
18180395
24036014
28733125
23727170
32098418
12122115
23202302
33910812
30297082
23465502
28870151
14613742
23622902
15809461
19406977
23993153
24492321
30415629
21986389
30415637
34554658
29080641
31669447
28784657
25006678
28488689
25713709
24876115
23463659
27421889
16380576
24529992
28768705
34603696
28346348
23991423
27190392
33895867
23467111
22337679
24052631
29562593
33115916
31005969
20876671",Effects of Vitamin D,"Reduced 25-hydroxyvitamin D (25[OH]D) metabolism and secondary hyperparathyroidism are common with lower estimated glomerular filtration rate (eGFR) and may contribute to cardiovascular disease and cancer risk.
We assessed for heterogeneity by baseline eGFR of the effects of vitamin D
Baseline eGFR was available for 15,917 participants. Participants' mean age was 68 years, and 51% were women. Vitamin D
We observed no significant heterogeneity by baseline eGFR in the effects of vitamin D","['cholecalciferol', 'dietary supplements', 'mineral metabolism', 'neoplasms']",Kidney360,2023-01-03,"[{'lastname': 'Limonte', 'firstname': 'Christine P', 'initials': 'CP', 'affiliation': 'Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.\nKidney Research Institute, University of Washington, Seattle, Washington.'}, {'lastname': 'Zelnick', 'firstname': 'Leila R', 'initials': 'LR', 'affiliation': 'Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.\nKidney Research Institute, University of Washington, Seattle, Washington.'}, {'lastname': 'Hoofnagle', 'firstname': 'Andrew N', 'initials': 'AN', 'affiliation': 'Kidney Research Institute, University of Washington, Seattle, Washington.\nDepartment of Laboratory Medicine, University of Washington, Seattle, Washington.'}, {'lastname': 'Thadhani', 'firstname': 'Ravi', 'initials': 'R', 'affiliation': 'Office of the Chief Academic Officer, Mass General Brigham, Boston, Massachusetts.'}, {'lastname': 'Melamed', 'firstname': 'Michal L', 'initials': 'ML', 'affiliation': 'Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.'}, {'lastname': 'Mora', 'firstname': 'Samia', 'initials': 'S', 'affiliation': ""Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.\nDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'lastname': 'Cook', 'firstname': 'Nancy R', 'initials': 'NR', 'affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Luttmann-Gibson', 'firstname': 'Heike', 'initials': 'H', 'affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Sesso', 'firstname': 'Howard D', 'initials': 'HD', 'affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Lee', 'firstname': 'I-Min', 'initials': 'IM', 'affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Buring', 'firstname': 'Julie E', 'initials': 'JE', 'affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Manson', 'firstname': 'JoAnn E', 'initials': 'JE', 'affiliation': ""Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'de Boer', 'firstname': 'Ian H', 'initials': 'IH', 'affiliation': 'Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.\nKidney Research Institute, University of Washington, Seattle, Washington.'}]",,,"Baseline eGFR was available for 15,917 participants. Participants' mean age was 68 years, and 51% were women. Vitamin D",Copyright © 2022 by the American Society of Nephrology.,"10.34067/KID.0006472022
10.1016/j.jmpt.2016.02.001
10.1161/CIRCULATIONAHA.107.706127
10.1016/j.ypmed.2013.08.026
10.1016/j.jaut.2017.07.007
10.1016/S0140-6736(13)60595-4
10.3390/nu12020575
10.1172/JCI0215219
10.3390/toxins4110962
10.21873/invivo.12387
10.1053/j.ajkd.2018.06.031
10.1016/j.semnephrol.2012.12.016
10.1186/s12882-017-0705-4
10.1016/j.ehj.2003.09.010
10.1016/j.ahj.2013.02.014
10.7326/0003-4819-142-7-200504050-00008
10.1681/ASN.2008090998
10.1053/j.ajkd.2013.07.008
10.1038/nrneph.2014.8
10.1056/NEJMoa1809944
10.1016/j.cct.2011.09.009
10.1056/NEJMoa1811403
10.1056/NEJMoa2102953
10.1016/j.ecl.2017.07.012
10.1016/j.cct.2019.105854
10.2215/CJN.01870217
10.1371/journal.pone.0099461
10.1038/ejcn.2017.59
10.1093/ckj/sfu122
10.1681/ASN.2013060604
10.1002/ijc.28144
10.1186/s12885-016-2532-6
10.2105/AJPH.2004.045260
10.1016/j.chembiol.2013.12.016
10.2215/CJN.00530117
10.1093/ckj/sfab035
10.3390/nu9040328
10.1155/2013/864012
10.1093/ndt/gfw080
10.1007/s00223-021-00844-1
10.1159/000346846
10.1001/jama.2012.120
10.1681/ASN.2013010103
10.3390/nu10030366
10.1681/ASN.2020050625
10.1093/ajcn/nqy378
10.2215/CJN.03940510",<Element 'PubmedArticle' at 0x12ec672e0>,No Effect,"15,917",Analysis,[],No Trend/Correlation Discovered,
5,"36416841
16453090
22269621
22658145
27231796
29545393
23546564
25464233
32956601
25838999
27798247
21728907
19100953
30415629
31669447
35717999
29684661
17634462
21118827
21646368
36049498
32023375
27578103
28476288
25545331",Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo.,"Statin-associated muscle symptoms (SAMS) are common and may lead to discontinuation of indicated statin therapy. Observational studies suggest that vitamin D therapy is associated with reduced statin intolerance, but no randomized studies have been reported.
To test whether vitamin D supplementation was associated with prevention of SAMS and a reduction of statin discontinuation.
Men 50 years or older and women 55 years or older, free of cancer and cardiovascular disease, were enrolled in a randomized, placebo-controlled, double-blind clinical trial of vitamin D supplementation. Participants who initiated statin therapy after randomization were surveyed in early 2016. The data were analyzed in early 2022.
Daily cholecalciferol (2000 international units) or placebo with assessment of statin prescriptions during follow-up.
Muscle pain or discomfort lasting several days (primary outcome) and discontinuation of a statin due to SAMS (secondary outcome).
Statins were initiated by 1033 vitamin D-assigned participants and 1050 placebo-assigned participants; mean (SD) age was 66.8 (6.2) years and 49% were women. Over 4.8 years of follow-up, SAMS were reported by 317 participants (31%) assigned vitamin D and 325 assigned placebo (31%). The adjusted odds ratio (OR) was 0.97 (95% CI, 0.80-1.18; P = .78). Statins were discontinued by 137 participants (13%) assigned to vitamin D and 133 assigned to placebo (13%) with an adjusted OR of 1.04 (95% CI, 0.80-1.35; P = .78). These results were consistent across pretreatment 25-hydroxy vitamin D levels (interaction P value = .83). Among participants with levels less than 20 ng/mL, SAMS were reported by 28 of 85 vitamin D-assigned participants (33%) and 33 of 95 placebo-assigned participants (35%). For those with levels less than 30 ng/ml, SAMS were reported by 88 of 330 vitamin-D assigned participants (27%) and 96 of 323 of placebo-assigned participants (30%).
Vitamin D supplementation did not prevent SAMS or reduce statin discontinuation. These results were consistent across pretreatment 25-hydroxy vitamin D levels.
ClinicalTrials.gov Identifier: NCT01169259.",[],JAMA cardiology,2022-11-24,"[{'lastname': 'Hlatky', 'firstname': 'Mark A', 'initials': 'MA', 'affiliation': 'Stanford University School of Medicine, Stanford, California.'}, {'lastname': 'Gonzalez', 'firstname': 'Pedro Engel', 'initials': 'PE', 'affiliation': 'Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'lastname': 'Manson', 'firstname': 'JoAnn E', 'initials': 'JE', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Buring', 'firstname': 'Julie E', 'initials': 'JE', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Lee', 'firstname': 'I-Min', 'initials': 'IM', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Cook', 'firstname': 'Nancy R', 'initials': 'NR', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Mora', 'firstname': 'Samia', 'initials': 'S', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.\nDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'lastname': 'Bubes', 'firstname': 'Vadim', 'initials': 'V', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'lastname': 'Stone', 'firstname': 'Neil J', 'initials': 'NJ', 'affiliation': 'Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}]",,,"Statins were initiated by 1033 vitamin D-assigned participants and 1050 placebo-assigned participants; mean (SD) age was 66.8 (6.2) years and 49% were women. Over 4.8 years of follow-up, SAMS were reported by 317 participants (31%) assigned vitamin D and 325 assigned placebo (31%). The adjusted odds ratio (OR) was 0.97 (95% CI, 0.80-1.18; P = .78). Statins were discontinued by 137 participants (13%) assigned to vitamin D and 133 assigned to placebo (13%) with an adjusted OR of 1.04 (95% CI, 0.80-1.35; P = .78). These results were consistent across pretreatment 25-hydroxy vitamin D levels (interaction P value = .83). Among participants with levels less than 20 ng/mL, SAMS were reported by 28 of 85 vitamin D-assigned participants (33%) and 33 of 95 placebo-assigned participants (35%). For those with levels less than 30 ng/ml, SAMS were reported by 88 of 330 vitamin-D assigned participants (27%) and 96 of 323 of placebo-assigned participants (30%).",,"10.1001/jamacardio.2022.4250
10.1007/s10557-005-5686-z
10.1016/j.amjmed.2011.08.007
10.1016/j.jacl.2012.03.003
10.18553/jmcp.2016.22.6.685
10.1161/CIRCOUTCOMES.117.004249
10.7326/0003-4819-158-7-201304020-00004
10.1016/j.ijcard.2014.10.118
10.1007/978-3-030-33304-1_14
10.7326/M20-4680
10.4103/1947-2714.153919
10.1177/0897190016674407
10.1185/03007995.2011.598144
10.1016/j.trsl.2008.11.002
10.1056/NEJMoa1809944
10.1016/j.cct.2019.105854
10.1016/j.ahj.2022.06.001
10.1016/j.atherosclerosis.2018.04.009
10.1056/NEJMra070553
10.1210/jc.2010-2704
10.1210/jc.2011-0385
10.1016/S0140-6736(22)01545-8
10.1056/NEJMra1907805
10.1016/j.jacl.2016.05.002
10.1016/S0140-6736(17)31075-9
10.1016/j.atherosclerosis.2014.12.016",<Element 'PubmedArticle' at 0x12ec94680>,No Effect,2083,Randomized Control Trials,['Muscle Symptoms'],No Trend/Correlation Discovered,Muscle Symptoms
6,"36364809
28094599
28884317
30011816
33531437
33783821
32929196
32179384
20139241
27716304
25835235
26024057
32770972
21646368
25327435
22613271
19414839
18492750
18991184
26053339
27569392
28216084
35373871
32620963
25899914
34950828
35676320
35309867
21415774
18089691
29852980
31284304",Efficacy and Safety of a Personalized Vitamin D,"A personalized vitamin D3 loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D3 daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D > 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (n = 5 in verum and n = 1 in the placebo group; p = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D3 daily sustained the achieved levels.","['bolus', 'calcium', 'colorectal cancer', 'efficacy', 'loading dose', 'personalized medicine', 'randomized controlled trial', 'safety', 'treatment regimen', 'vitamin D']",Nutrients,2022-11-12,"[{'lastname': 'Kuznia', 'firstname': 'Sabine', 'initials': 'S', 'affiliation': 'Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.\nMedical Faculty Heidelberg, Heidelberg University, 69117 Heidelberg, Germany.'}, {'lastname': 'Czock', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, 69120 Heidelberg, Germany.'}, {'lastname': 'Kopp-Schneider', 'firstname': 'Annette', 'initials': 'A', 'affiliation': 'Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.'}, {'lastname': 'Caspari', 'firstname': 'Reiner', 'initials': 'R', 'affiliation': 'Clinic Niederrhein (A Clinic of the German Pension Insurance Rhineland), 53474 Bad Neuenahr-Ahrweiler, Germany.'}, {'lastname': 'Fischer', 'firstname': 'Harald', 'initials': 'H', 'affiliation': 'Clinic Rosenberg (A Clinic of the German Pension Insurance Westfalen), 33014 Bad Driburg, Germany.'}, {'lastname': 'Laetsch', 'firstname': 'Dana Clarissa', 'initials': 'DC', 'affiliation': 'Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.'}, {'lastname': 'Slavic', 'firstname': 'Marija', 'initials': 'M', 'affiliation': 'Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.'}, {'lastname': 'Brenner', 'firstname': 'Hermann', 'initials': 'H', 'affiliation': 'Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.\nDivision of Preventive Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.\nNational Center for Tumor Diseases (NCT), German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.'}, {'lastname': 'Schöttker', 'firstname': 'Ben', 'initials': 'B', 'affiliation': 'Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.'}]",,,,,"10.3390/nu14214546
10.1080/01635581.2017.1265131
10.1007/s10654-017-0298-z
10.3390/nu10070896
10.1158/1055-9965.EPI-20-1388
10.1002/ijc.33580
10.1038/s41416-020-01060-8
10.1016/j.nut.2020.110734
10.1530/EJE-09-0932
10.1186/s12937-016-0203-8
10.1024/0300-9831/a000192
10.1093/nutrit/nuu004
10.1186/s12885-020-07219-z
10.1210/jc.2011-0385
10.3109/10408363.2014.970266
10.1016/j.maturitas.2012.04.011
10.7326/0003-4819-150-9-200905050-00006
10.1210/jc.2008-0350
10.1080/03009740802419081
10.1111/cen.12836
10.1038/aps.2016.82
10.1016/j.jsbmb.2017.01.021
10.1111/joim.13494
10.1210/clinem/dgaa432
10.1007/s40266-015-0259-8
10.1002/jbm4.10567
10.1038/s41416-022-01850-2
10.1002/jbm4.10606
10.2310/JIM.0b013e318214ea2d
10.1210/jc.2007-2308
10.1016/j.jacc.2018.04.020
10.7326/M19-0341",<Element 'PubmedArticle' at 0x12ec9fe20>,No Effect,None,None,['None'],None,None
7,"36285795
16529140
25419853
18385669
17942703
30415629
21986389
16825677
18541590
16481636
12588750
10465168
25559473
20346624
27512104
2542376
28251933
23149428
18180395
24026071
8601621
9139959
17690094
32899880
9915270
6549286
22337679
28346348
16112052
31709816
32578850
19687350
9133508
15326072
19770405
20980215
30383226",Impact of Vitamin D3 Versus Placebo on Cardiac Structure and Function: A Randomized Clinical Trial.,"Background Vitamin D supplementation leads to regression of left ventricular (LV) hypertrophy and improves LV function in animal models. However, limited data exist from prospective human studies. We examined whether vitamin D supplementation improved cardiac structure and function in midlife/older individuals in a large randomized trial. Methods and Results The VITAL (Vitamin D and OmegA-3 Trial) was a nationwide double-blind, placebo-controlled randomized trial that tested the effects of vitamin D3 (2000 IU/d) and n-3 fatty acids (1 g/d) on cardiovascular and cancer risk in 25 871 individuals aged ≥50 years. We conducted a substudy of VITAL in which participants underwent echocardiography at baseline and 2 years. Images were interpreted by a blinded investigator at a central core laboratory. The primary end point was change in LV mass. Among 1054 Greater Boston-area participants attending in-clinic visits, we enrolled 1025 into this study. Seventy-nine percent returned for follow-up and had analyzable echocardiograms at both visits. At baseline, the median age was 64 years (interquartile range, 60-69 years), 52% were men, and 43% had hypertension. After 2 years, the change in LV mass did not significantly differ between the vitamin D and placebo arms (median +1.4 g versus +2.6 g, respectively; ","['cardiac structure and function', 'echocardiography', 'n−3 fatty acids', 'randomized controlled trial', 'vitamin D']",Journal of the American Heart Association,2022-10-27,"[{'lastname': 'Chandra', 'firstname': 'Alvin', 'initials': 'A', 'affiliation': 'Department of Internal Medicine UT Southwestern Medical Center Dallas TX.'}, {'lastname': 'Picard', 'firstname': 'Michael H', 'initials': 'MH', 'affiliation': 'Massachusetts General Hospital and Harvard Medical School Boston MA.'}, {'lastname': 'Huang', 'firstname': 'Shi', 'initials': 'S', 'affiliation': 'Department of Biostatistics Vanderbilt University Medical Center Nashville TN.\nVanderbilt Translational and Clinical Cardiovascular Research Center Vanderbilt University School of Medicine Nashville TN.'}, {'lastname': 'Gupta', 'firstname': 'Deepak K', 'initials': 'DK', 'affiliation': 'Vanderbilt Translational and Clinical Cardiovascular Research Center Vanderbilt University School of Medicine Nashville TN.'}, {'lastname': 'Agusala', 'firstname': 'Kartik', 'initials': 'K', 'affiliation': 'Department of Internal Medicine UT Southwestern Medical Center Dallas TX.'}, {'lastname': 'Buring', 'firstname': 'Julie E', 'initials': 'JE', 'affiliation': ""Division of Preventive Medicine Brigham and Women's Hospital, Harvard Medical School Boston MA.""}, {'lastname': 'Lee', 'firstname': 'I-Min', 'initials': 'IM', 'affiliation': ""Division of Preventive Medicine Brigham and Women's Hospital, Harvard Medical School Boston MA.""}, {'lastname': 'Cook', 'firstname': 'Nancy R', 'initials': 'NR', 'affiliation': ""Division of Preventive Medicine Brigham and Women's Hospital, Harvard Medical School Boston MA.""}, {'lastname': 'Manson', 'firstname': 'JoAnn E', 'initials': 'JE', 'affiliation': ""Division of Preventive Medicine Brigham and Women's Hospital, Harvard Medical School Boston MA.\nDepartment of Epidemiology Harvard T. H. Chan School of Public Health Boston MA.""}, {'lastname': 'Thadhani', 'firstname': 'Ravi I', 'initials': 'RI', 'affiliation': 'Mass General Brigham Boston MA.'}, {'lastname': 'Wang', 'firstname': 'Thomas J', 'initials': 'TJ', 'affiliation': 'Department of Internal Medicine UT Southwestern Medical Center Dallas TX.'}]",,,,,"10.1161/JAHA.121.025008
10.4065/81.3.353
10.7326/M14-2450
10.1038/ki.2008.101
10.1073/pnas.0611202104
10.1056/NEJMoa1809944
10.1016/j.cct.2011.09.009
10.1093/ajcn/87.6.1952
10.1056/NEJMoa055222
10.1161/01.ATV.0000057393.97337.AE
10.1016/j.echo.2014.10.003
10.1016/j.jclinepi.2010.03.004
10.1007/978-3-319-19425-7
10.1161/CIRCHEARTFAILURE.115.002978
10.1172/JCI114097
10.3945/ajcn.116.140392
10.1161/CIRCOUTCOMES.112.967604
10.1161/CIRCULATIONAHA.107.706127
10.1152/ajpregu.00322.2013
10.1172/JCI118582
10.1152/ajpheart.1997.272.4.H1751
10.1074/jbc.M705495200
10.3390/ijms21186483
10.1016/S0272-6386(99)70260-X
10.1001/jama.2012.120
10.3390/nu9040328
10.1053/j.ajkd.2005.04.031
10.1161/CIRCULATIONAHA.119.044645
10.1093/eurheartj/ehaa419
10.1161/HYPERTENSIONAHA.109.130641
10.1161/01.CIR.95.8.2007
10.1161/01.CIR.0000141573.44737.5A
10.1161/HYPERTENSIONAHA.109.136655
10.1016/j.jash.2010.09.003
10.1210/jc.2018-01414",<Element 'PubmedArticle' at 0x12ecc89f0>,No Effect,N/A,Randomized Clinical Trial,['Cardiac Structure and Function'],N/A,Cardiac Structure and Function
8,"36098968
23395245
11253156
27402367
24833586
30115829
30415637
30415629
29165531
27125943
33007912
31567003
24291279
30784011
20335313
31609228
12806071
18826625
29917058
30307533
25697060
26944937
30132204
26755682
28242579
25880068
16398907
32145016
31559418
11897015
23746838
35838044
27697810
29722845
31840808
33170239
18165842
25033068
29677308
28461159
32492153
22732551
25127502
29328894
36098163
24028357
34637524",Effect of Vitamin D3 and Omega-3 Fatty Acid Supplementation on Risk of Frailty: An Ancillary Study of a Randomized Clinical Trial.,"Preventive strategies for frailty are needed. Whether supplements with anti-inflammatory properties, such as vitamin D3 or marine omega-3 fatty acids, are useful for frailty prevention is unknown.
To test the effects of vitamin D3 and omega-3 supplements on change in frailty in older individuals.
This study was conducted in 2021, as a prespecified ancillary to the Vitamin D and Omega-3 (VITAL) trial, a 2 × 2 factorial randomized clinical trial. A total of 25 871 individuals (men aged ≥50 years and women aged ≥55 years), without cancer or cardiovascular disease and with data on frailty, were recruited across all 50 US states from November 2011 to March 2014 and followed up through December 31, 2017. Data analysis for the ancillary study was conducted from December 1, 2019, to March 30, 2022.
Vitamin D3, 2000 IU/d, and marine omega-3 fatty acids, 1 g/d.
Frailty was measured using a validated 36-item frailty index that includes measures of function, cognition, mood, and comorbidities from annual questionnaires. Change in frailty score from baseline to year 5, according to randomization, using an intention-to-treat protocol, was assessed using repeated measures. Cox proportional hazards regression models assessed incident frailty. In subgroup analysis, an alternative frailty definition, the physical phenotype, was used as a sensitivity analysis.
Of 25 871 VITAL trial participants randomized, 25 057 had sufficient data to calculate a frailty index. Baseline mean (SD) age was 67.2 (7.0) years, and 12 698 (50.7.%) were women. Mean (SD) frailty score was 0.109 (0.090) (range, 0.00-0.685), and 3174 individuals (12.7%) were frail. During a median 5-year follow-up, mean (SD) frailty scores increased to 0.121 (0.099) (range, 0.00-0.792). Neither vitamin D3 nor omega-3 fatty acid supplementation affected mean frailty scores over time (mean difference at year 5: vitamin D3, -0.0002; P = .85; omega-3 fatty acid, -0.0001; P = .90) or rate of change in mean frailty score (interaction with time: vitamin D3; P = .98; omega-3 fatty acid; P = .13) Incident frailty remained similar over time (interaction with time: vitamin D3, P = .90; omega-3 fatty acid; P = .32). Results were unchanged using the frailty physical phenotype.
In this ancillary study of the VITAL randomized clinical trial, treatment with vitamin D3 or omega-3 fatty acid supplementation, compared with placebo, did not affect the rate of frailty change or incidence over time. These results do not support routine use of either vitamin D3 or omega-3 fatty acid supplementation for frailty prevention in generally healthy community-dwelling older adults not selected for vitamin D3 deficiency.
ClinicalTrials.gov Identifier: NCT01169259.",[],JAMA network open,2022-09-14,"[{'lastname': 'Orkaby', 'firstname': 'Ariela R', 'initials': 'AR', 'affiliation': ""New England Geriatric Research, Education, and Clinical Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts.\nDivision of Aging, Brigham and Women's Hospital, Boston, Massachusetts.\nHarvard Medical School, Boston, Massachusetts.""}, {'lastname': 'Dushkes', 'firstname': 'Rimma', 'initials': 'R', 'affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'lastname': 'Ward', 'firstname': 'Rachel', 'initials': 'R', 'affiliation': 'New England Geriatric Research, Education, and Clinical Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts.\nHarvard Medical School, Boston, Massachusetts.\nMassachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts.'}, {'lastname': 'Djousse', 'firstname': 'Luc', 'initials': 'L', 'affiliation': ""Division of Aging, Brigham and Women's Hospital, Boston, Massachusetts.\nHarvard Medical School, Boston, Massachusetts.\nMassachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts.""}, {'lastname': 'Buring', 'firstname': 'Julie E', 'initials': 'JE', 'affiliation': ""Harvard Medical School, Boston, Massachusetts.\nDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Lee', 'firstname': 'I-Min', 'initials': 'IM', 'affiliation': ""Harvard Medical School, Boston, Massachusetts.\nDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Cook', 'firstname': 'Nancy R', 'initials': 'NR', 'affiliation': ""Harvard Medical School, Boston, Massachusetts.\nDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'LeBoff', 'firstname': 'Meryl S', 'initials': 'MS', 'affiliation': ""Harvard Medical School, Boston, Massachusetts.\nEndocrinology, Diabetes, and Hypertension Division, Brigham and Women's Hospital, Boston, Massachusetts.\nDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'lastname': 'Okereke', 'firstname': 'Olivia I', 'initials': 'OI', 'affiliation': 'Harvard Medical School, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.\nDepartment of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.'}, {'lastname': 'Copeland', 'firstname': 'Trisha', 'initials': 'T', 'affiliation': 'Harvard Medical School, Boston, Massachusetts.'}, {'lastname': 'Manson', 'firstname': 'JoAnn E', 'initials': 'JE', 'affiliation': ""Harvard Medical School, Boston, Massachusetts.\nDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.\nDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.""}]",,,"Of 25 871 VITAL trial participants randomized, 25 057 had sufficient data to calculate a frailty index. Baseline mean (SD) age was 67.2 (7.0) years, and 12 698 (50.7.%) were women. Mean (SD) frailty score was 0.109 (0.090) (range, 0.00-0.685), and 3174 individuals (12.7%) were frail. During a median 5-year follow-up, mean (SD) frailty scores increased to 0.121 (0.099) (range, 0.00-0.792). Neither vitamin D3 nor omega-3 fatty acid supplementation affected mean frailty scores over time (mean difference at year 5: vitamin D3, -0.0002; P = .85; omega-3 fatty acid, -0.0001; P = .90) or rate of change in mean frailty score (interaction with time: vitamin D3; P = .98; omega-3 fatty acid; P = .13) Incident frailty remained similar over time (interaction with time: vitamin D3, P = .90; omega-3 fatty acid; P = .32). Results were unchanged using the frailty physical phenotype.",,"10.1001/jamanetworkopen.2022.31206
10.1016/S0140-6736(12)62167-9
10.1093/gerona/56.3.M146
10.1016/j.cjca.2016.03.020
10.1093/gerona/glu057
10.3390/nu10081099
10.1056/NEJMoa1811403
10.1056/NEJMoa1809944
10.1016/j.maturitas.2016.04.009
10.3390/nu12103005
10.1161/JAHA.119.013543
10.1016/j.jacc.2013.09.070
10.1007/s40520-019-01146-1
10.7326/0003-4819-152-11-201006010-00232
10.1016/S0140-6736(19)31786-6
10.1100/tsw.2001.58
10.1186/1471-2318-8-24
10.1093/gerona/gly134
10.1093/gerona/gly232
10.1016/j.archger.2015.01.016
10.1093/ageing/afw039
10.1007/s40520-018-1023-9
10.1093/gerona/glv228
10.1016/j.archger.2017.02.009
10.1186/s12916-015-0328-1
10.1111/j.1532-5415.2005.00506.x
10.1093/gerona/glaa003
10.1093/gerona/glz197
10.1186/1471-2318-2-1
10.1016/j.cell.2013.05.039
10.1172/JCI158448
10.7861/clinmedicine.16-5-455
10.1093/ajcn/nqy026
10.1111/jgs.16286
10.1001/jama.2020.16909
10.1007/BF02982161
10.1210/jc.2014-1742
10.1001/jama.2017.21640
10.1016/S2213-8587(17)30103-1
10.1210/clinem/dgaa311
10.1016/j.tcm.2012.04.005
10.1016/j.jamda.2014.06.013
10.3949/ccjm.85a.17075
10.1016/S2666-7568(20)30059-3
10.1111/jgs.12420
10.1093/gerona/glab312",<Element 'PubmedArticle' at 0x12ecec040>,No Effect,"25,871",Randomized Clinical Trial,['Frailty Index'],No Trend/Correlation Discovered,Frailty Index
9,"36079732
28423084
33981041
34391943
3321363
20377107
30474045
31657690
28577789
22830639
29111233
22095260
30336639
35876758
32344708
19172691
32965012
32498216
17764205
6513613
3974610
25210461
27274758
22034510
33617971
10774463
31340751
27424994
0
18586856
25912039
1597660
25096007
23840373
23830380
35182667
31126033
26170625
21067953
30501009",Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study.,"Elderly people are at high risk of suffering from infection and being affected by severe forms of disease because their immunosystem suffers from aging. The alteration of normal immune functions causes the increase of pro-inflammatory cytokines which can expose these people to increased risk of developing pathologies as cancer, diabetes, and/or arthritis. Some supplements could be helpful for restoring normal immune functions. We conducted a case-control study to evaluate the efficacy of a supplement containing Sambucus nigra, zinc, tyndallized Lactobacillus acidophilus (HA122), arabinogalactans, vitamin D, vitamin E, and vitamin C to improve the inflammatory levels (IL-6 and CRP) and to modulate the lymphocytes growth. Additionally, we analyzed wellness by self-questionnaire. This study had two control group: a young group and an elderly one. Our study showed that treating elderly patients with the supplement for 30 days improved IL-6, CRP, and lymphocytes levels; the result was independent from the dosage of the supplements used. Elderly patients, despite the improvement, were not able to reach the same conditions of young patients; however, most of the patients (>70%) claimed to “feel better” after the use of the supplement. The use of this supplement should be considered at a low dosage for a prolonged period to reduce inflammation and modulate immune senescence in patients over 60 years old.","['aging', 'immuno-senescence', 'inflammatory cytokines', 'nutraceuticals', 'oral supplement', 'vitamin C', 'vitamin D', 'zinc']",Nutrients,2022-09-10,"[{'lastname': 'Maselli Del Giudice', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Department Otorhinolaryngology, Hospital of Barletta, 76121 Barletta (BT), Italy.'}, {'lastname': 'La Mantia', 'firstname': 'Ignazio', 'initials': 'I', 'affiliation': 'Department GF Ingrassia, University of Catania, 95123 Catania, Italy.'}, {'lastname': 'Barbara', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': 'Department Otorhinolaryngology, University Hospital of Bari, 70126 Bari, Italy.'}, {'lastname': 'Ciccarone', 'firstname': 'Silvana', 'initials': 'S', 'affiliation': 'Department Otorhinolaryngology, Hospital of Barletta, 76121 Barletta (BT), Italy.'}, {'lastname': 'Ragno', 'firstname': 'Maria Sterpeta', 'initials': 'MS', 'affiliation': 'Department Otorhinolaryngology, Hospital of Barletta, 76121 Barletta (BT), Italy.'}, {'lastname': 'de Robertis', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'Department Otorhinolaryngology, Hospital of Barletta, 76121 Barletta (BT), Italy.'}, {'lastname': 'Cariti', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': 'Department Otorhinolaryngology, Hospital of Barletta, 76121 Barletta (BT), Italy.'}, {'lastname': 'Barbara', 'firstname': 'Michele', 'initials': 'M', 'affiliation': 'Department Otorhinolaryngology, Hospital of Barletta, 76121 Barletta (BT), Italy.'}, {'lastname': ""D'Ascanio"", 'firstname': 'Luca', 'initials': 'L', 'affiliation': 'Department Otorhinolaryngology, Azienda Ospeliera Riunita Marche Nord (AORMN), 61032 Fano (PU), Italy.'}, {'lastname': 'Di Stadio', 'firstname': 'Arianna', 'initials': 'A', 'affiliation': 'Department GF Ingrassia, University of Catania, 95123 Catania, Italy.'}]",,,,,"10.3390/nu14173476
10.1590/0001-3765201720160487
10.1038/s41586-021-03547-7
10.1016/j.arr.2021.101422
10.1093/clinids/9.6.1127
10.1016/j.anai.2009.11.009
10.1155/2018/8653572
10.2174/1573399815666191024085838
10.1016/j.nutres.2017.02.001
10.1186/1742-4933-9-15
10.1016/j.exger.2017.10.024
10.1007/s11357-011-9341-2
10.3390/nu10101531
10.1080/1744666X.2022.2106217
10.3390/nu12041193
10.1038/nri2378
10.26355/eurrev_202009_22869
10.3390/nu12061637
10.1016/0047-6374(84)90152-0
10.1016/0165-1161(85)90015-9
10.4137/NMI.S17245
10.1186/s12979-016-0076-x
10.1161/ATVBAHA.111.236349
10.1016/j.joca.2021.01.008
10.1146/annurev.med.51.1.245
10.1186/s12876-019-1047-4
10.1186/s13054-016-1208-6
10.1113/expphysiol.2008.043190
10.3390/nu7043011
10.3109/08923979209009228
10.1371/journal.pone.0065835
10.1016/j.jep.2022.115116
10.3390/ijms20102534
10.2147/DDDT.S83144
10.1016/j.jbspin.2010.09.018
10.1002/iub.1976",<Element 'PubmedArticle' at 0x138007b50>,No Effect,N/A,Case-Control Study,['N/A'],N/A,N/A
